Kalaris Therapeutics, Inc.
KLRS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001754068
No open-market purchases or sales by Kalaris Therapeutics, Inc. insiders were filed in the last 90 days; 56 institutions reported holding it in 13F filings for Q2 2026, worth $73.4M in total; no superinvestor holds it.
13F holders, Q2 2025
Institutional positions in Kalaris Therapeutics, Inc. as of Jun 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 30
- −2 vs. Q1 2025
- Shares held
- 13.4M
- −512.0K (−3.7%) vs. Q1 2025
- Total value
- $35.7M
- −$75.7M (−68.0%) vs. Q1 2025
- New holders
- 4
- 9 more added
- Sold out
- 6
- 7 more reduced
Compare with Q1 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting KLRS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 56 | $73.4M |
| Q1 2026 | 58 | $107.2M |
| Q4 2025 | 51 | $151.9M |
| Q3 2025 | 32 | $76.4M |
| Q2 2025 | 30 | $35.7M |
| Q1 2025 | 32 | $111.4M |
| Q4 2024 | 53 | $20.7M |
| Q3 2024 | 60 | $36.3M |
| Q2 2024 | 72 | $33.9M |
| Q1 2024 | 77 | $36.4M |
| Q4 2023 | 82 | $28.5M |
| Q3 2023 | 90 | $115.5M |
| Q2 2023 | 94 | $183.6M |
| Q1 2023 | 89 | $156.0M |
| Q4 2022 | 86 | $193.1M |
| Q3 2022 | 87 | $293.7M |
| Q2 2022 | 84 | $109.6M |
| Q1 2022 | 84 | $184.1M |
| Q4 2021 | 84 | $329.4M |
| Q3 2021 | 80 | $640.3M |
| Q2 2021 | 84 | $521.8M |
| Q1 2021 | 75 | $624.4M |
Institutions, Q2 2025
Shares, value and share of portfolio for each institution holding Kalaris Therapeutics, Inc.; share changes are against Q1 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Royal Bank of Canada | 85 | $0 | 0.00% | +85 | New |
| SBI Securities Co., Ltd. | 10 | $27 | 0.00% | +10 | New |
| Farther Finance Advisors, LLC | 33 | $88 | 0.00% | 00.0% | Unchanged |
| Parallel Advisors, LLC | 49 | $131 | 0.00% | 00.0% | Unchanged |
| JPMorgan Chase & Co | 50 | $134 | 0.00% | −245−83.1% | Reduced |
| BNP Paribas Arbitrage, SA | 141 | $376 | 0.00% | +14+11.0% | Added |
| Bank of America Corp | 273 | $729 | 0.00% | −5,151−95.0% | Reduced |
| Federated Hermes, Inc. | 634 | $1.69K | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 1,964 | $5.24K | 0.00% | +668+51.5% | Added |
| Tower Research Capital LLC (TRC) | 2,153 | $5.75K | 0.00% | +719+50.1% | Added |
| Raymond James Financial Inc | 2,629 | $7.02K | 0.00% | +2,629 | New |
| UBS Group AG | 4,116 | $11.0K | 0.00% | −5,145−55.6% | Reduced |
| FMR LLC | 7,806 | $20.8K | 0.00% | 00.0% | Unchanged |
| State Street Corp | 10,710 | $28.6K | 0.00% | 00.0% | Unchanged |
| Marshall Wace, LLP | 14,115 | $37.7K | 0.00% | 00.0% | Unchanged |
| RBF Capital, LLC | 17,391 | $46.4K | 0.00% | 00.0% | Unchanged |
| Two Sigma Advisers, LP | 20,281 | $54.1K | 0.00% | −1,300−6.0% | Reduced |
| XTX Topco Ltd | 24,234 | $64.7K | 0.00% | +24,234 | New |
| Geode Capital Management, LLC | 25,476 | $68.0K | 0.00% | −1,311−4.9% | Reduced |
| BlackRock, Inc. | 38,156 | $101.9K | 0.00% | +10,642+38.7% | Added |
| Millennium Management LLC | 54,092 | $144.4K | 0.00% | +37,510+226.2% | Added |
| Squarepoint Ops LLC | 59,095 | $157.8K | 0.00% | +44,508+305.1% | Added |
| Redmile Group, LLC | 82,955 | $221.5K | 0.02% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 96,751 | $258.3K | 0.00% | +77,500+402.6% | Added |
| Vanguard Group Inc | 129,839 | $346.7K | 0.00% | +14,753+12.8% | Added |
| Siren, L.L.C. | 282,586 | $754.5K | 0.04% | 00.0% | Unchanged |
| Gilead Sciences, Inc. | 317,789 | $848.5K | 0.07% | −405,484−56.1% | Reduced |
| Octagon Capital Advisors LP | 360,000 | $961.2K | 0.21% | −121,000−25.2% | Reduced |
| Tang Capital Management LLC | 360,859 | $963.5K | 0.05% | +51,638+16.7% | Added |
| Samsara BioCapital, LLC | 11,448,081 | $30.6M | 6.25% | 00.0% | Unchanged |
| EcoR1 Capital, LLC | 0 | $0 | 0.00% | −201,718−100.0% | Sold out |
| Woodline Partners LP | 0 | $0 | 0.00% | −21,519−100.0% | Sold out |
| Susquehanna International Group, LLP | 0 | $0 | 0.00% | −13,796−100.0% | Sold out |
| Coldstream Capital Management Inc | 0 | $0 | 0.00% | −208−100.0% | Sold out |
| EverSource Wealth Advisors, LLC | 0 | $0 | 0.00% | −30−100.0% | Sold out |
| Barclays PLC | 0 | $0 | 0.00% | −1−100.0% | Sold out |